Our Company

1-7 of 7

Understanding biosimilars and projecting the cost savings to employers: Update26 August 2015 - By Frank R. Kopenski and Katie Holcomb - Article

This paper focuses on new information over the past several years about the U.S. market for biosimilars and how the cost savings impact may emerge over the next five years through 2019.

Understanding biosimilars and projecting the cost savings to employers06 April 2012 - By Frank R. Kopenski - Article
This study quantifies the impact of biosimilar savings and analyses the potential drivers of cost savings and their variability.Assessing the future basis of drug pricing01 February 2009 - By Frank R. Kopenski - Article

This white paper outlines problems the healthcare industry has experienced with using average wholesale price (AWP) for determining medication reimbursement levels. Our expert examines two possible pricing methods that might replace AWP—average sales price and average manufacturer price. Studies showed

Prescription drug benefit design: The building blocks and their impact on cost01 October 2008 - By Frank R. Kopenski - Article
The impact of healthcare benefit changes on high-cost utilizers01 November 2007 - By Frank R. Kopenski - Article
BP, Fall 200730 October 2007 - By Alan H. Perry and Frank R. Kopenski - Article

This issue features: "Prescription drug benefit design: The building blocks and their impact on cost," and "DB plan risk management: finding a better match between assets and liabilities."

Financial review of prescription drug component of Medicare Prescription Drug, Improvement and Modernization Act of 200301 November 2003 - By Frank R. Kopenski and Bill J. Thompson and and Chuck Miller - Article

/uploadedFiles/insight/research/health-rr/archive/Financial-Review-Prescription-Drug-RR11-26-03.pdf


  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman